Prescription drug · ANDA
Methimazole NDC 50268-496
Methimazole 10 mg/1 · Tablet · Oral · AvPAK
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50268-496-15 | 50268049615 | 50 BLISTER PACK in 1 BOX (50268-496-15) / 1 TABLET in 1 BLISTER PACK (50268-496-11)Marketed from Oct 13, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Methimazole
- Generic name (nonproprietary)
- methimazole
- Active ingredients
- Methimazole — 10 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- AvPAK
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 218149
- Marketing start
- Listing expires
- Other FDA classes
- Thyroid Hormone Synthesis Inhibitors (Mechanism)
- Identifiers
- Product ID 50268-496_41168239-a16a-40e0-e063-6294a90a5c58SPL ID 41168239-a16a-40e0-e063-6294a90a5c58SPL set ID 4116774b-6c2b-2c74-e063-6394a90a4955RxCUI 197941, 197942UNII 554Z48XN5E
- Pharmacologic class
- Thyroid Hormone Synthesis Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N450268049615followed by a unit qualifier and the quantityPackage 50268-0496-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Methimazole tablets are indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option. To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 218149
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Methimazole | Methimazole 10 mg/1 | TabletOral | Bionpharma Inc. | 69452-329 |
| Methimazole | Methimazole 5 mg/1 | TabletOral | Bionpharma Inc. | 69452-328 |
| Methimazole | Methimazole 5 mg/1 | TabletOral | AvPAK | 50268-495 |